Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.